Outcome of patients diagnosed with fibrinous pleuritis after medical thoracoscopy  by Metintas, Muzaffer et al.
Respiratory Medicine (2012) 106, 1177e1183Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedOutcome of patients diagnosed with fibrinous
pleuritis after medical thoracoscopyMuzaffer Metintas a,*, Guntulu Ak a, Omer Cadirci a, Huseyin Yildirim a,
Emine Dundar b, Selma Metintas ca Eskisehir Osmangazi University, Medical Faculty, Department of Chest Diseases, Eskisehir, Turkey
b Eskisehir Osmangazi University, Medical Faculty, Department of Pathology, Eskisehir, Turkey
c Eskisehir Osmangazi University, Medical Faculty, Department of Public Health, Eskisehir, Turkey
Received 4 December 2011; accepted 24 April 2012
Available online 17 May 2012KEYWORDS
Mesothelioma;
Pleura;
Diagnosis;
Thoracoscopy* Corresponding author. Tel.: þ90 22
E-mail addresses: muzaffermetin
heylul2002@yahoo.com (H. Yildirim),
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2012.04.009Summary
Background: In patients with post- medical thoracoscopy histopathological diagnoses of
fibrinous pleuritis, confusion can occur concerning subsequent procedures. This issue is partic-
ularly important in regions where mesothelioma is prevalent. We aimed to identify false nega-
tives among patients where mesothelioma was common due to asbestos exposure whose
histopathological diagnosis following thoracoscopy was fibrinous pleuritis. We also determined
risk factors associated with patients that required additional advanced invasive procedures for
diagnosis.
Methods: Overall, 287 patients who underwent thoracoscopy were included in the study.
Patients diagnosed with fibrinous pleuritis as a result of thoracoscopy were followed for 2 years
regarding this condition. More invasive procedures were performed on patients who showed no
recuperation or developed pleural disease again during the follow-up period.
Results: Fibrinous pleuritis was observed in 101 (35.2%) patients. Follow-up of these patients
revealed that the false negative rate was 18% for malignant pleural diseases. The thoracosco-
pist’s opinion regarding the pleural space, computed tomography scan findings indicating
malignancy, pain and female gender were determined to be risk factors for malignant pleural
diseases.
Conclusions: In regions where mesothelioma is prevalent and one of the above-stated risk
factors is present, patients whose post-thoracoscopy histopathological diagnosis is fibrinous
pleuritis should be treated with a more advanced invasive diagnosis procedure.
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ThoracoscopyMedical thoracoscopy (MT) is increasingly being utilized in
the diagnosis of pleural diseases following undiagnosed
pleural effusion cytology and/or needle biopsy because MT
procedures have a 90% success rate for the diagnosis of
malignant pleural diseases and pleural tuberculosis.1e5
However, in the patients except malignant pleural
diseases or tuberculosis, histopathological changes on
pleural biopsy samples are always reported as fibrinous
pleuritis.6e8 While the diagnosis of fibrinous pleuritis may
be preserved in some of these cases through other clinical,
radiological or effusion findings, in the remaining cases,
problems can occur in clinics because concerns exist
whether this histopathological diagnosis points to a benign
disease, or if MT observation and sampling failed to prop-
erly identify a malignancy.
This study aimed to evaluate the proportion of false-
negative results for malignant pleural diseases among
patients in a region with a high incidence rate of malignant
mesothelioma with a post-MT histopathological diagnosis of
fibrinous pleuritis; and determine the epidemiological,
clinical, radiological and laboratory characteristics of
patients initially diagnosed with fibrinous pleuritis con-
cerning the prediction of malignant pleural disease.
Methods and materials
This study was conducted in the Chest Diseases Department
of theMedical Faculty of Eskisehir Osmangazi University from
January 2002 to January 2009. The studywas approved by the
Ethical Committee of Eskisehir Osmangazi University (2010/
245, PR-10-09-23-10). A trial registration was also performed
(Clinicaltrials.gov Identifier: NCT01196585).
In 2002, a database for pleural diseases was created and
prospectively filled in the department. All pleural disease
cases and their associated data with the indications for
thoracoscopy or other invasive procedures have been added
into this database.
Patients
Consecutive patients who underwent MT for diagnostic
purposes were invited to participate in this study. They
were those in whom the cause of the pleural fluid was not
identified by the clinical examinations or the laboratory
and imaging findings and who had negative pleural fluid
cytology.3,4 These patients were thoroughly informed
before undergoing MT, and all of the patients provided
informed written consent.
The patients whose histopathological diagnoses were
reported to be fibrinous pleuritis were monitored at
reasonable intervals for at least 24 months following MT by
clinical examination and by imaging modalities, including
computerized tomography scans. During follow-up, VATS or
open surgical biopsy were performed for final diagnosis in
the patients whose pleural pathology did not recuperate or
stabilize or whose pleural pathology recurred. The patients
whose final diagnosis could not be obtained were excluded
from the study.Medical thoracoscopy procedures were performed by
a team that consisted of M. M. plus G. A. or M. M. plus H. Y.
In each case, a rigid thoracoscope (Karl Storz, Tuttlingen,
Germany) was utilized under mild sedation and local
anesthesia. Biopsy samples were taken for histopatholog-
ical investigation and, if necessary, for microbiological
investigation as previously defined.1,9 During the MT
procedure, at least 8 biopsy samples, 7 from different sites
and one from the diaphragmatic parietal pleura, were
obtained from all of the patients. Occasionally, the number
of biopsy samples increased according to the distribution
pattern of the lesions and the appearance of the pleura. We
also obtained a biopsy sample from the visceral pleura if
there was a pathological appearance. Otherwise, a biopsy
sample was not obtained routinely from the visceral pleura.
We did not obtain biopsy samples from the fissure or the
pericardium. If there was a lesion at any location on the
pleura or a large lesion on the lung that could be defined as
a large nodule or a mass, at least 3 additional biopsy
samples were obtained from these lesions. In each case of
normal-appearing pleura, we obtained one biopsy specimen
from this tissue exactly over the rib. Because obtaining the
biopsy specimen from the intact pleura in conscious,
sedated patients would be very painful, we sprayed local
anesthetic on the biopsy area. However, due to widespread
pathological changes to the pleura, we could not locate any
intact pleural area in some patients. In contrast, in patients
with an entirely normal-appearing pleural space, we also
sprayed local anesthetic on the biopsy area and obtained at
least 6 biopsy specimens: one from the superior costal
pleura, two from the mid-costal pleura, two from the
inferior costal pleura and one over the diaphragm.
After MT, the impression of the thoracoscopists and the
thoracoscopic findings regarding pleural appearance, nod-
ularity, irregular or smooth thickening, hyperemia, pla-
ques, inflammation and normal conditions were
documented. Histopathological results, microbiological
results, early and late complications of MT, other diagnostic
or therapeutic procedures and treatment outcomes were
also recorded.Histopathological evaluation of samples
Biopsy samples were evaluated by the Department of
Pathology of the Medical Faculty of Eskisehir Osmangazi
University. The cases were primarily categorized as benign
and malignant; malignant patients were also categorized
according to cellular properties. Positive and negative
mesothelial immunomarkers were used to differentiate
tumors of mesothelial origin from those of epithelial origin.
Negative mesothelial immunomarkers included carcinoem-
bryonic antigen (CEA), Ber Ep4, B 72.3, MOC-31 and CD 15
(Leu-M1), while positive mesothelial immunomarkers
included calretinin, Wilm’s tumor 1 (WT-1), cytokeratin
5/6, mesothelin, mesothelioma (HBME-1), and N-cadherin.
Additionally, epithelial membrane antigen (EMA), desmin,
vimentin, p53, pan-cytokeratin, TTF-1, cytokeratin 7, and
cytokeratin 20 were used when required. In the granulo-
matous lesions, periodic acid- Schiff (PAS) and
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investigate the presence of fungi and acid-resistant bacilli
(Mycobacterium tuberculosis), respectively.
Histological diagnosis of fibrinous pleuritis was defined
according to previous reports.1,6 Briefly, if the histology
report of the pleural tissue revealed any of the following,
we identified these cases as fibrinous pleuritis: reactive
fibrous pleural thickening, fibrinous pleurisy, fibrosis,
fibrous connective tissue, chronic inflammation, benign
changes in the absence of malignant pleural infiltration,
granulomata, pleural vasculitis or evidence of bacterial
infection.1,6
Risk factors
A two-phase study was performed to determine predictive
risk factors for false-negative results in relation to malig-
nant pleural involvement among the patients with MT-
diagnosed fibrinous pleuritis. In the first phase, the
impression of the thoracoscopist concerning the pleural
space during the MT was accepted as a possible risk factor.
It was evaluated separately from patient variables because
it was the opinion of the doctor rather than a patient
characteristic. The sensitivity, specificity, positive predic-
tive value (PPV) and negative predictive value (NPV) of the
thoracoscopist’s impression were calculated in regards to
malignant pleural involvement.
In the second phase, risk factors including gender;
smoking status; asbestos exposure; computed tomography
findings indicating malignant pleural involvement; pain;
hemorrhagic pleural effusion; the presence of elevated
(above 30%) mesothelial cells and/or the presence of
clustered, atypical mesothelial cells (cell balls) in the
pleural fluid were evaluated by uni- and multivariate
analysis for false-negative results in relation to malignant
pleural involvement.
Thoracoscopic impression
The thoracoscopic impression was classified as malignant,
benign or indeterminate.1,5
Malignant pleural impression
Nodules on pleura; nodular invasion; mass on pleura;
pleural thickening, including hyperemia with varying levels
of invasion and irregular manifestation characteristics; and
typical lymphangitic involvement. While one of the above-
stated cases was present, observation of non-calcified or
calcified pleural plaques did not change the impression of
malignant pleural involvement.
Benign pleural impression
A typical case makes the structures under the pleura visible
and shows no other changes. Grey-beige-iridescent fibrous
plaque formation in the pleura, normal pleural appearance,
calcified plaques, diffuse but smooth thickening of the
parietal and visceral pleura, diffuse typical granuloma
appearance in the pleura, typical small nodular appearance
in relation to rheumatoid arthritis in the pleura with fibrous
protrusions, and typical infection findings in the pleura
were considered benign.Indeterminate impression
If no certain opinion was provided with regard to either of
the categories, an impression of “pleural pathology with no
certain division between benign and malignant” was
considered to be acceptable.
CT scan findings suggesting pleural malignancy
One or more of the following CT findings were accepted as
factors that suggested malignant pleural diseases: “rind-
like pleural involvement”; “mediastinal pleural involve-
ment”; “pleural nodularity”; “pleural thickness greater
than 1 cm” and invasion of thoracic structures such as
pericardium, chest wall, diaphragm, and mediastinum.10,11
Statistical analysis
The data were analyzed using the Statistical Package for
the Social Sciences v 13.5 (SPSS Inc, Chicago, IL, USA; www.
qrsinternational.com). Predictive factors of false negative
biopsy results were first compared according to background
characteristic categories using the X2 test and an unad-
justed logistic regression model. Multiple regression models
were applied in the second step to identify independent
risk factors for predictive factors of false negative biopsy
results. For multivariate analysis, we included outcome
predictors as assessed in univariate analysis. Hosmer and
Lemeshow statistics was used to determine sensitivity and
specificity of the model and to assess suitability. The effi-
ciency of MT for achieving the final diagnosis and the val-
idity of observation made by thoracoscopist during the
procedure were calculated; additionally, their sensitivity,
specificity, PPV, NPV and 95% confidence interval (CI) values
were calculated.Results
During the study period, MT procedures were performed on
355 patients. MT was performed for the purposes of diag-
nosis in 320 of the 355 patients. Of the 320 patients, 13
patients could not be followed for the specified period
following the procedure. In seven patients, the presence of
pleural fluid resolved without treatment during the follow-
up period. These patients were considered to have idio-
pathic plural effusions. Thirteen patients remain in follow-
up. As a result, the MT procedures of 287 patients were
included in the study. The overall study group was
comprised of 160 (55.7%) men and 127 (44.3%) women. The
mean age for men was 60.9  12.2 years; for women, the
mean age was 61.1  12.3 years. The overall mean age of
the patient population was 61.0  12.2 years. The final
diagnostic distribution of cases is shown in Table 1.
The diagnostic methods and the results for the 287
patients who underwent diagnostic MT procedures are
shown in Fig. 1.
While histopathological examinations provided a specific
diagnosis in 186 (64.8%) of 287 patients, the histopatho-
logical result was recorded as fibrinous pleuritis in 101
(35.2%) patients. The distribution of diagnoses obtained as
a result of histopathological examination of tissue samples
Table 1 Diagnoses of 287 patients, whose data were
taken into account.
Diagnosis Female Male Number (%)
Mesothelioma 58 50 108 (37.6)
Metastatic malignant
pleural effusion
32 36 68 (23.7)
Lymphoma 4 5 9 (3.1)
Tuberculous pleurisy 7 13 20 (7.0)
Meigs syndrome 2 e 2 (0.7)
Chilothorax 1 e 1 (0.4)
Paramalignant pleural
effusion
4 8 12 (4.2)
Benign asbestos pleurisy 6 33 39 (13.6)
Parapneumonic pleural
effusion
1 2 3 (1.0)
Rheumatoid pleural
effusion
e 7 7 (2.4)
Cardiac pleural effusion 5 5 10 (3.4)
Renal failure 2 e 2 (0.7)
Hepatic pleural effusion 2 e 2 (0.7)
Pulmonary thromboembolism 2 e 2 (0.7)
Radiotherapy related
pleural effusion
1 e 1 (0.4)
Viral pleuritis e 1 1 (0.4)
All 127 160 287 (100)
Table 2 Distribution of patients subjected to a histo-
pathological diagnosis following MT and the final diagnosis
at follow-up.
Diagnosis Working diagnosis
(%)
Final diagnosis
(%)
Mesothelioma 92 (85.2) 108
Metastatic malignant
pleural effusion
66 (97.1) 68
Lymphoma 9 (100) 9
Tuberculous pleurisy 19 (95.0) 20
Fibrinous pleuritis 101 (18.8a) 82
Total 287 287
a False negativity rate for malignant pleural disease and
pleurisy tuberculosis.
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after follow-up of the patients is presented in Table 2.
In 3 of 9 patients who were diagnosed with lymphoma
and subjected to MT, a final diagnosis was determined for
lymphoma. However, in the remaining 6 patients, the
histopathological assessment of biopsy tissues indicated
lymphohematogenous malignant pleural involvement, and
a certain diagnosis of lymphoma was not made. For this
reason, it was suggested that lymph node sampling proce-
dures should be performed. Therefore, all 6 of the
remaining patients were diagnosed with lymphoma as
a result of additional invasive procedures.
The number of patients with a final diagnosis of malig-
nant mesothelioma, metastatic malignant pleural effusion,Figure 1 Diagnostic distribution of patients undergoing
medical thoracoscopy.lymphoma or pleurisy tuberculosis as a result of post-MT
histopathological examination was 205. In these patients,
the rate of achieving a final diagnosis through MT was
determined to be 90.7% (186/205). MT diagnostic sensitivity
was the lowest for malignant mesothelioma, with a diag-
nostic sensitivity of 85.2% (95% CI, 81.09e89.31). For this
group, MT diagnosis had a specificity of 100, with PPV and
NPV of 100 and 91.8, respectively (95% CI, 88.63e94.97).
Among 287 patients available for the evaluation, 18 out
of 101 patients whose histopathological diagnosis was
initially reported as fibrinous pleuritis were identified as
having malignant pleural pathology during the follow-up
period. Thus, the false negativity for malignancy in 287
patients was 6.3% (18/287). When the case of pleurisy
tuberculosis, which was diagnosed as false negative
following MT, was excluded, the false negative rate of MT
biopsy-diagnosed fibrinous pleuritis for malignant pleural
disease was 18% (18/100). Of these 18 cases, 16 patients
were diagnosed with malignant mesothelioma and 2 with
metastatic malignant pleural involvement.
To reduce the occurrence of false negatives for malig-
nant pleural involvement in relation to post-MT histopath-
ological diagnosis, an analysis was made of the possible risk
factors. In the first phase, the relationship between the
thoracoscopist’s observation of the pleural space and the
post-MT histopathological diagnosis was examined. The
distribution of the thoracoscopist’s impression according to
the final diagnosis in 101 patients initially diagnosed with
fibrinous pleuritis is given in Table 3.
According to the data presented in Table 3, in the event
that the thoracoscopist’s impression of the appearance of
the pleural space was malignant, the sensitivity was 76.9%
(95% CI, 67.9e85.9), and the specificity was 93.1% (95% CI,
87.7e98.5); additionally, the PPV was 66.7% (95% CI,
56.7e76.7), and the NPV was 95.7% (95% CI, 91.4e100.0). In
the event that the thoracoscopist’s impression of the
appearance of the pleural space was malignant or inde-
terminate for malignant involvement, the sensitivity for
malignant pleural involvement was 83.3% (95% CI,
76.0e90.6) and the specificity was 80.7% (95% CI,
73.0e88.4); the PPV and NPV were 48.4% (95% CI,
38.7e58.2) and 95.7% (95% CI, 91.7e99.7), respectively.
For the patients with MT-diagnosed fibrinous pleuritis,
other predictive factors for false-negative biopsy results for
malignant pleural disease were evaluated by uni- and
Table 3 Distribution of the final diagnosis according to the thoracoscopist’s impression in patients initially diagnosed with
fibrinous pleuritis.
Thoracoscopic impression Final diagnosis malign (%) Final diagnosis benign (%) Total
Malign 10 (66.7) 5 (33.3) 15
Benign 3 (04.3) 67 (95.7) 70
Indeterminate 5 (31.3) 11 (68.7) 16
Total 18 83 101
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presented in Table 4.
While the variables of female gender, asbestos expo-
sure, CT scan findings indicating malignant pleural
involvement and complaints regarding pain were found to
be significant according to univariate analysis, the variables
of female gender, CT scan findings and complaints
regarding pain were considered independent variables
according to multivariate analysis.
Discussion
Although the ability of MT to provide specific histopatho-
logical diagnosis for cancer and tuberculous pleurisy is
quite high, a considerable amount of patients who undergo
MT are diagnosed with fibrinous pleuritis because all benign
pleural pathologies, excluding pleural tuberculosis, provide
a diagnosis of fibrinous pleuritis.6,7 Therefore, when clin-
ical, radiological and laboratory findings are not definitive,
it becomes difficult for clinicians to delineate between
benign diseases and malignant diseases utilizing only diag-
nostic MT procedures; further, confusion can occur with
regard to the steps taken following diagnosis.Table 4 Results of factors predictive for false negative biopsy
Variable % Univariate analysis
OR (95% CI)
Gender
Male 11.1 1
Female 31.6 3.69 (1.30e10.46)
Smoking
No 23.7 1
Yes 12.2 0.45 (0.15e1.36)
Asbestos exposure
No 3.6 1
Yes 25.0 9.00 (1.14e71.04)
CT scan findings
No 11.6 1
Yes 38.5 4.77 (1.62e14.04)
Pain
No 8.2 1
Yes 31.3 5.11 (1.55e16.82)
Hemorrhagic pleural effusion
No 14.6 1
Yes 30.8 2.59 (0.69e9.78)
Increased mesothelial cells/cell balls
No 14.9 1
Yes 33.3 2.86 (0.99e8.29)
OR: Odds ratio value.The rate of MT samples histopathologically determined
to be “fibrinous pleuritis” varies between 9% and 50%.1,6
Among these patients, false negatives range between 5%
and 25.5% for malignant pleural disease.12e14 In a recent
study, the rate for fibrinous pleuritis diagnosis was 31%,
with a false-negative rate of 12%.1 In our study, 35%
(101/287) of 287 cases were diagnosed as fibrinous pleur-
itis. Of these 101 cases, 18 patients did present with
malignant pleural disease, and 1 patient had tuberculosis
pleurisy. Given these rates of false-negative results, the
question remains whether a clinician should “wait and
see”, as proposed by certain authors as described below, or
request a more advanced invasive procedure because of
the chance of malignant disease in patients whose post-MT
histopathological diagnosis was fibrinous pleuritis. Addi-
tionally, the length and follow-up regime for these patients
have yet to be defined.1,6,14,15 The responses to these
questions are becoming increasingly important due to the
distinctive rise in the incidence of malignant pleural
diseases and malignant mesothelioma.1,14e16
According to the literature, two methods can be applied
in relation to this issue. First, a “wait and see” approach
can be utilized for the majority of these patients becauseresult among patients with a diagnosis of fibrinous pleuritis.
Multivariate analysis
P OR (95% CI) P
0.014 1
4.36 (1.27e14.89) 0.019
0.155
0.037
0.005 1 0.033
3.86 (1.11e13.43)
0.007 1
3.81 (1.03e14.12) 0.045
0.096
0.052
1182 M. Metintas et al.the rate of false negatives is not high. However, if there are
adhesions in the pleural space that prohibit the MT proce-
dure, then VATS or open surgical biopsy should be
proposed, especially if there is a clinical suspicion of
mesothelioma.13,14 Otherwise, the patients should be
monitored through chest X-rays, and MT should be repeated
if the pleural effusion persists or increases with lympho-
cytosis or an increased level of LDH.13 According to the
other view, because no clinical or radiological predictors
for pleural malignancy have been assessed in the studies,
each patient should be considered on a case-by-case basis,
with the approach depending on the clinical suspicion and
whether the patient is fit and willing to tolerate general
anesthesia. In a recent study, asbestos exposure, smoking,
pleural effusion size, presence of previous malignant
diseases and the thoracoscopist’s impression of the
macroscopic appearance of the pleural space were
analyzed as risk factors. However, the authors concluded
that there was no correlation between the diagnosis of
malignant pleural diseases and any of these factors.1 Future
studies are needed in which appropriate patients should be
selected based on risk factors after negative or nonspecific
pleural biopsies from MT to undergo more invasive surgical
procedures.1,14
To this end, we used a two-step method in our study.
First, we analyzed the efficiency of the thoracoscopist’s
impression of malignancy during the MT procedure. As this
property was an impression rather than a patient charac-
teristic, it was evaluated independently from the patient
variables as a risk factor indicating malignant pleural
involvement (Table 3).
In the event that the thoracoscopist’s impression of the
appearance of the pleural space was malignant or inde-
terminate for malignant involvement, the sensitivity and
specificity for malignant pleural involvement were high
(83.3% and 80.7%, respectively). However, if the thor-
acoscopist’s impression of the pleural space was not
malignant or indeterminate, the chance of a benign pleural
pathology was very high (95.7%). Thus, we believe that if
a thoracoscopist’s impression of a patient is indeterminate
or suggestive of malignant pleural involvement, the
recommendation for VATS or open surgical biopsy should
occur. In contrast, if a thoracoscopist’s observation is
benign, then the “wait and see” method may be preferred,
assuming that the patient does not exhibit any other risk
factor discussed below.
When risk factors indicating malignant pleural involve-
ment were analyzed for the patients diagnosed with fibri-
nous pleuritis (Table 4), CT scan findings indicating
malignant involvement, complaints concerning pain and
female gender were found to be significant variables in
multivariate analysis.
CT scan findings indicating malignant involvement are
important, as was shown in previous studies.10,11 Pain
should be considered to be a highly suggestive finding for
malignant mesothelioma in patients with pleural effusion
and asbestos exposure.11,15 In our study, the observation
that pain was a significant risk factor may be attributed to
the fact that the majority of the undiagnosed cases (16/18;
88.9%) were malignant mesothelioma. Similarly, female
gender was a significant risk factor in our study. In our study
area, which was rural, asbestos exposure is common, andthe malignant mesothelioma incidence for the exposed
population was 114.8/100,000 for men and 159.8/100,000
for women. These figures indicate that the risk of malignant
mesothelioma is 88.3 and 799 times greater in men and
women, respectively, than for similar groups in the rest of
the world.17 Malignant mesothelioma development is more
prevalent in women exposed to asbestos in our region.
Women have a higher cumulative exposure to asbestos than
men because of lifestyle and the division of labor in rural
areas. The mean cumulative exposures to asbestos were 4.0
fiber-years/ml for women with a median exposure duration
of 52 years and 2.7 fiber-years/ml for men with a median
exposure duration of 55 years (p < 0.001). As for compar-
ison among women living in rural areas, it may be suggested
that a highly elevated risk for mesothelioma in asbestos-
exposed women is associated with a higher level of
asbestos exposure.17,18 In a study from Wittenoom, the
authors concluded that, after residential exposure to
asbestos, women exhibited a doseeresponse curve that was
significantly steeper than that observed in men.19
False negativities through post-MT histopathological
analysis for malignant pleural involvement appear to be
locally affected by the frequency of malignant mesothe-
lioma. In a study by Davies, cases of malignant mesothe-
lioma accounted for all of the false negative results.1 In our
study, false negatives predominantly resulted from cases of
malignant mesothelioma. When patients diagnosed with
tuberculosis pleurisy and metastatic pleural involvement
were excluded from the 101 cases, the false negative rate
for patients diagnosed with fibrinous pleuritis through post-
MT histopathological analysis for malignant mesothelioma
was 16.3% (16/98) for 98 fibrinous pleuritis cases; this ratio
becomes only 2.3% (2/84) for metastatic malignant pleural
involvement. Then, the diagnostic problem for MT, even if
the ratio is low, becomes striking for malignant mesothe-
lioma, as specified previously.20 MT false negative results
for malignant mesothelioma have generally been attributed
to pleural adhesions that limit inspection, very early
malignant mesothelioma in which the pleura appears
predominantly normal with only focal abnormalities, and
the thoracoscopist’s inexperience.4,21 In addition, because
neoplastic invasion in malignant mesothelioma occurs sub-
mesothelially,22 it may be difficult for a thoracoscopist to
detect these areas on grossly normal appearing pleura.
Consequently, in regions where malignant mesothelioma
is endemic, patients diagnosed with fibrinous pleuritis as
a result of post-MT histopathological analysis should be
recommended for VATS or open surgical biopsy as soon as
possible if the thoracoscopist’s impression is not benign
pleural inflammation, if the CT findings indicate malignant
pleural changes or if the patient has a pain on the effusion
side. In regions where environmental asbestos exposure
occurs, “female gender” should be accepted as a risk factor
for malignant pleural disease.Acknowledgments
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